PATIENTS WITH ADVANCED SQUAMOUS NSCLC ARE IN URGENT NEED OF OPTIONS THAT MAY DELIVER TUMOR RESPONSE3

Lung cancer histology4
40% of NSCLC are adenocarcinoma, 30% are squamous cell carcinoma, 15% are large cell, and 5% are other types of NSCLC - pie chart
~30% of lung cancers are squamous cell carcinoma
  • NSCLC=non–small cell lung cancer.
Squamous cell carcinomas
Squamous cell carcinoma - lung image
  • Associated with a poorer prognosis than nonsquamous3
  • Tumors are often centrally located5
  • Have been shown to grow twice as fast as adenocarcinoma6
  • Often seen extrinsically pushing into airway structures as they grow7
  • Associated with a history of smoking5
  • NSCLC=non–small cell lung cancer.
  • Importance of Tumor Response Rates

    RESPONSE RATES ARE HELPFUL IN ASSESSING CLINICAL BENEFIT

    ORR is a clinically meaningful endpoint in NSCLC trials, which can help physicians choose an appropriate treatment8
    Using ORR as an endpoint in oncology drug approval has a long history
    Response criteria have been used for more than 30 years9

    ORR=overall response rate.

    TUMOR RESPONSE IS A RIGOROUS MEASUREMENT8

    Spatial measurement of tumor shrinkage is a form of direct, real-­time clinical assessment11

    Measure of the greater unidimensional diameters

    RECIST Criteria10

    CR=complete response

    PR=partial response

    SD=stable disease

    PD=progressive disease

    CR

    Disappearance of all clinical and radiological evidence of target lesions

    PR

    ≥30% decrease of the greater unidimensional diameters

    SD

    Failure to observe CR or PR, but not PD

    PD

    ≥20% increase of the greater unidimensional diameters or presence of new lesion

    Measure of the greater
    unidimensional
    diameters RECIST CRITERIA10

    Complete Response (CR)

    Disappearance of all clinical and radiological evidence of target lesions

    Partial Response (PR)

    ≥30% decrease of the greater unidimensional diameters

    Stable Disease (SD)

    Failure to observe CR or PR, but not PD

    Progressive Disease (PD)

    ≥20% increase of the greater unidimensional diameters or presence of new lesion

    Response assessment under RECIST guidelines is based on measurement of the longest single-dimension diameters of target lesions, which are identified at baseline.
    RECIST=Response Evaluation Criteria In Solid Tumors.

    CLOSE THE TAB
YOU ARE NOW LEAVING www.abraxanepro.com
Additional Information for Readers Provided by Celgene Corporation

The clinical trial described in this article served as the
basis for the approval for ABRAXANE for Injectable Suspension.
The analyses contained in the article may differ from those in the package insert for ABRAXANE.

Please see Important Safety Information and Prescribing Information, including Boxed WARNING.

Click “OK” to proceed or “CANCEL” to return to
www.abraxanepro.com

OK
CANCEL